Advertisement

Drugs & Therapy Perspectives

, Volume 35, Issue 1, pp 47–47 | Cite as

Correction to: Ambrisentan ± tadalafil in WHO functional class II/III pulmonary arterial hypertension: a guide to its use in the EU

  • Katherine A. Lyseng-WilliamsonEmail author
  • Jürgen Behr
Correction

Correction to: Drugs & Therapy Perspectives  https://doi.org/10.1007/s40267-018-0531-1

Page 294, column 1, first sentence: the following text, which previously read:

“In a secondary analysis of survival outcomes in the modified intent-to-treat population of AMBITION, mortality rates did not differ to a significant extent between the ambrisentan + tadalafil and pooled monotherapy groups at the end of the 24-week trial (10 vs 14% of patients; HR 0.67; 95% CI 0.42–1.08; log-rank p = 0.10) [24]”.

Should read:

“In a secondary analysis of survival outcomes in the modified intent-to-treat population of AMBITION, mortality rates did not differ to a significant extent between the ambrisentan + tadalafil and pooled monotherapy groups at the end of the study (10 vs 14% of patients; HR 0.67; 95% CI 0.42–1.08; log-rank p = 0.10; median time on study drug 96 and 91 weeks, respectively) [24]”.

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand
  2. 2.Department of Internal Medicine V, Comprehensive Pneumology CentreUniversity of MunichMunichGermany

Personalised recommendations